# Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling

> **NCT02591888** · PHASE4 · TERMINATED · sponsor: **TriHealth Inc.** · enrollment: 18 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** Placebo
- **DRUG:** Liposomal bupivacaine

## Key facts

- **NCT ID:** NCT02591888
- **Lead sponsor:** TriHealth Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02
- **Primary completion:** 2017-03
- **Final completion:** 2017-12
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Difficult to enroll; since a similar research project on a different population showed no significance the study has been closed.
- **Last updated:** 2018-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02591888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02591888, "Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02591888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*